This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

21 Jun 2021

Press Release > CordenPharma Colorado Expands Lipid Excipients Purification

CP BotaniChol® is CordenPharma’s plant-based Cholesterol which stabilizes the LNP structures and facilitates endosome escape.

Luxembourg, 19 April 2021 -- In response to the COVID-19 pandemic, mRNA (messenger RNA) vaccines have catapulted to center stage of the pharmaceutical and biotechnology industry. As of early 2021, there are eight ongoing human trials for mRNA vaccines led by Moderna, BioNTech / Pfizer, CureVac, Sanofi / TranslateBio, Arcturus / Duke-NUS Medical School (Singapore), Imperial College London, Chulalongkorn University (Thailand), and Providence Therapeutics.

Due to the increasing demand since the beginning of the pandemic for mRNA COVID-19 vaccines formulated with Lipid NanoParticle (LNP) delivery systems, CordenPharma has been continuously investing in expanded lipid supply chain at our facilities in Switzerland, France, and Colorado.

CordenPharma manufactures four lipids that are typically used to formulate LNPs for various synthetic mRNA-based vaccines:

  • >> Cationic Lipids that encapsulate the negatively charged mRNA
  • >> PEGylated Lipids that help to form a protective hydrophilic layer which sterically stabilises the LNP
  • >> DiStearoylphosPhatidylCholine (DSPC), a phospholipid that provides a stable bilayer-forming structure
  • >> Plant-based Cholesterol (CP BotaniChol®) which stabilizes the LNP structures & facilitates endosome escape

LNP delivery systems not only efficiently express the mRNA-encoded immunogen after intramuscular injection, but also play an important role as adjuvants in vaccine reactogenicity. All four lipids components of an LNP delivery system require very high purity.

In order to accommodate this significant increase in market demand, CordenPharma is pleased to announce another major capital expenditure initiative, in addition to substantial investments in the past, which further enhances our lipid purification capacity in CordenPharma Colorado. The expansion includes additional production lines ready to be incorporated into the lipid manufacturing process as early as April 2021, confirming our leading position in both custom and Standard Lipids supply. By the end of July 2021, this investment will significantly decrease our lipid shipment delivery time.

CEO & President Dr. Michael Quirmbach comments, “CordenPharma is proud to contribute this major capital expansion to increase important lipid production for the global market. We have drawn upon longstanding expertise in specialized lipids to create an even stronger integrated network of facilities to support current and future projects.”

Mentioned Companies
Corden Pharma International GmbH
View company profile